Find Your Role in HIV Prevention: Strategies for Patient Communication, Telemedicine, and PrEP Implementation

Find Your Role in HIV Prevention: Strategies for Patient Communication, Telemedicine, and PrEP Implementation

Med-IQ Select

Developed in collaboration
Med-IQSouthern Medical Association

Online Course | Specialties: Family Medicine, Internal Medicine, Primary Care
Released: 6/2/2021
Expires: 6/1/2022
Max Credits: 1.5
Jump to Education

Latesha Elopre, MD
Assistant Professor, Division of Infectious Diseases
Director of Diversity and Inclusion, Graduate Medical Education
University of Alabama at Birmingham
Birmingham, AL

David Malebranche, MD, MPH
Board-Certified Internal Medicine Physician
Sexual Health and HIV Specialist
Atlanta, GA

Samantha Hill, MD, MPH
Assistant Professor
Director of Sexual Health and Reproductive Technologies
Department of Pediatrics, Division of Adolescent Medicine
The University of Alabama at Birmingham
Birmingham, AL

Activity Planners
Jaime Symowicz, PhD
Manager, Educational Strategy and Content
Baltimore, MD

Samantha Gordon, MS
Accreditation Manager
Baltimore, MD

Amy Sison
Director of CME
Baltimore, MD

Kathryn Schaefer, MSN, RN, CPHRM, CHCP
Associate Director, Education Quality and Compliance
East Lansing, MI

Jennifer S. Price, MA
Education Manager
Southern Medical Association
Birmingham, AL

Mandy Stone
CME Compliance Manager
Southern Medical Association
Birmingham, AL

Learning Objectives
Upon completion, participants should be able to:

  • Use respectful and sex-positive communication strategies when talking to patients about their sexual history and HIV risk during telemedicine visits
  • Summarize evidence-based recommendations for PrEP indications, eligibility screening, treatment, and monitoring
  • Implement a comprehensive approach to initiate and support PrEP use for eligible patients

Target Audience
This activity is intended for primary care physicians, NPs, PAs, nurses, and pharmacists.

Statement of Need
In 2019, the US Department of Health and Human Services proposed the Ending the HIV Epidemic: A Plan for America initiative, with the goal of reducing new HIV infections by 75% by 2025 and by 90% by 2030. Prevention of new HIV transmissions using proven interventions, including pre-exposure prophylaxis (PrEP), is one strategy of this multifaceted approach. Although the South represents 52% of new HIV diagnoses in the United States, people living in the South are underserved by PrEP relative to their epidemic need, which is demonstrated by this region having the lowest PrEP-to-need ratio compared with the West, Midwest, and Northeast. To address gaps in PrEP uptake and care, primary care providers (physicians, NPs, PAs, nurses) and pharmacists need to play a greater role in initiating and supporting PrEP use in patients who have an increased risk of acquiring HIV. However, many primary care providers and pharmacists lack up-to-date knowledge about PrEP implementation, including PrEP eligibility screening, available PrEP options, and patient monitoring and follow-up. In addition, both healthcare providers and patients can be uncomfortable discussing sexual health and behavior, frequently avoiding this topic due to stigma, provider interpersonal bias, provider concern with encouraging risky behavior, or patient fear of being seen as promiscuous. Moreover, the COVID-19 pandemic has disrupted PrEP implementation with many healthcare providers shifting to telemedicine for PrEP-related visits, creating additional challenges for primary care providers who have less experience talking to patients about their sexual health and need for PrEP.

Collaboration Statement
This activity was developed by Med-IQ in collaboration with the Southern Medical Association.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Med-IQ is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This nursing activity has been approved for up to 1.5 contact hours.

ACPEMed-IQ is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) of credit for pharmacists. ACPE #0476-0000-21-004-H01-P. This knowledge-based activity is designed for all pharmacists.

Medium/Method of Participation
This is a 1.5-credits CE activity. To receive credit, read the introductory CE material, complete all of the modules, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Initial Release Date: June 2, 2021
Expiration Date: June 1, 2022
Estimated Time to Complete This Activity: 1 hour and 30 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as those in any amount occurring within the past 24 months, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Off-label/unapproved drug uses or products are mentioned within this activity.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.

Latesha Elopre, MD
Principal Investigator: Merck & Co., Inc.

Samantha Hill, MD, MPH, has indicated no real or apparent conflicts.

David Malebranche, MD, MPH
Consulting fees/advisory boards: Gilead Sciences, Inc., Johnson & Johnson, ViiV Healthcare

The peer reviewers and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email

System Requirements



  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit:

This activity is available free of charge to participants.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Gilead Sciences, Inc


The following material has been developed to accompany this activity:

Guidance for Sexual History and Health Conversations With Patients

Note: This material is not accredited for CME and, therefore, does not offer any CME/CE credit.


Here are the key takeaways from this activity. Deeper insights and evidence, patient communication videos, and learning modules, plus an opportunity to receive credit, are available at the "Continue" button below.

  • PrEP is an HIV-prevention strategy that can reduce the risk of sexual HIV transmission by up to 99% and has the potential to significantly reduce the rate of HIV acquisition in populations disproportionately affected by HIV but is currently underused among these individuals
  • To address gaps in PrEP uptake and care, primary care providers (physicians, NPs, PAs, and nurses) and pharmacists have been called upon to play a greater role in identifying individuals with a greater risk of HIV acquisition and initiating and supporting PrEP for eligible patients
  • To determine whether patients have an indication for PrEP, it is important to discuss their sexual health and behaviors using nonjudgmental, respectful language and by asking open-ended questions
  • PrEP should be considered for individuals who have an increased risk of HIV acquisition and are interested in taking a pharmacologic option to prevent HIV, including MSM, transgender women, heterosexual men and women, and PWID
  • Currently, 2 fixed-dose PrEP formulations approved by the US FDA are available as once-daily pills: TDF/FTC and TAF/FTC
  • Non-daily PrEP (also known as event-driven PrEP, on-demand PrEP, or PrEP 2-1-1) is considered an off-label use in the United States, but guidance from the WHO states that it may be considered for MSM who have infrequent sex
  • Ongoing monitoring for individuals taking PrEP includes routine clinical visits with a healthcare provider for HIV and STI screening, laboratory tests, and assessments for PrEP adherence and adverse effects
  • The COVID-19 pandemic has led to a greater use of telemedicine for PrEP-related visits as well as changes in patients’ needs for PrEP
  • Update: In December 2021, the FDA approved cabotegravir (extended-release injectable suspension) for PrEP, and the CDC released updated PrEP clinical practice guidelines.

View reference list.

Click “Continue” to proceed through this activity and receive credit, or select a specific module from the menu on the left.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.